Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Twist Bioscience to Present at Upcoming Investor Conferences


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:

Both of these presentations will be webcast live and can be accessed by visiting the "Presentations" page of the investor relations section of the company's website here. Replays of the presentations will be archived for a period of 90 days following the conclusion of the live event.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube


These press releases may also interest you

at 07:05
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
Volastra Therapeutics, a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer...

at 07:03
AHP Backed Prolerity Clinical Research Appoints Drew Domescik as CFO
Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer. Prolerity currently owns and operates 11 research sites across...

at 07:02
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients, and Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced a new...

at 07:00
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGrafttm
via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics, Inc. ("Qualigen")  to advance the commercialization of Marizyme's first-in-class FDA cleared...

at 07:00
Nobias Therapeutics Joins NVIDIA Inception Program for Startups
Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to...

at 07:00
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination...

More news about Health...


News published on and distributed by: